LRRK2 & Parkinson's - Drs. Behrouz, Alessi, Fell, Padmanabhan, and West

At this week's Round Table Discussion, Dr. Spring Behrouz, CEO and Co-Founder of Vincere Biosciences, discusses LRRK2's role in Parkinson's disease (PD) with experts Drs. Dario Alessi, Matthew Fell, Shalini Padmanabhan, and Andy West.

#openscience #discussion #research #science #biology #brain #vincere #dundee #merck #michaeljfoxorg #duke #parkinsons #lrrk2 #therapeutics #aging

Link to full articles:
https://pubmed.ncbi.nlm.nih.gov/29855...
https://pubmed.ncbi.nlm.nih.gov/38438...
https://pubmed.ncbi.nlm.nih.gov/38368...
https://pubmed.ncbi.nlm.nih.gov/34340...
https://pubmed.ncbi.nlm.nih.gov/38293...
https://pubmed.ncbi.nlm.nih.gov/31461...
https://pubmed.ncbi.nlm.nih.gov/35895...

Dr. Alessi's Profile:
Profile: https://www.dundee.ac.uk/people/dario...

Dr. Fell's Profile and Social Media:
LinkedIn:   / matthew-fell-6936862  
Twitter:   / mjfell1979  

Dr. Padmanabhan's Social Media:
LinkedIn:   / shalini-padmanabhan  

Dr. West's Profile and Social Media:
Profile: https://scholars.duke.edu/person/andr...
Twitter:   / dukewestlab  

Dr. Spring Behrouz Social Media:
LinkedIn:   / bahareh  
Twitter:   / dr_behrouz  

Chapters:

00:00-02:14 Introduction
02:15-07:45 How LRRK2 Contributes to PD
07:46-11:30 LRRK2 and GBA
11:31-17:51 LRRK2 and Synuclein
17:52-22:25 LRRK2 and VPS35
22:26-29:34 LRRK2 and the Pink/parkin Pathway
29:35-36:13 LRRK2 and Cell Types
36:14-50:53 LRRK2 Therapeutics in Clinical Trials
50:54-56:11 LRRK2 Therapeutics and Idiopathic PD
56:12-56:33 Conclusion